
ACR 2026 real-world data associate upadacitinib with greater joint count reductions than IL-17 inhibitors after prior TNF inhibitor use.

Jessica Walsh, MD, is a rheumatologist at the Salt Lake City Veterans Affairs Health Care System and University of Utah Health.